FIA
IBIO icon

FNY Investment Advisers’s iBio IBIO Stock Holding History

FNY Investment Advisers’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,000
Closed -$36 – 596
2024
Q1 		$36 Buy
+9,000
New +$11.3K 0.02% 302

Other funds holding IBIO

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FNY Investment Advisers's IBIO Position: Q2 2024 in Review

FNY Investment Advisers sold out of iBio (IBIO) in Q2 2024, closing a stake of 9,000 shares — an estimated $36 sold.

FNY Investment Advisers first reported a position in IBIO in Q1 2024 and held it in 1 quarter. The position peaked at $36 in Q1 2024. 28 funds tracked by Wall St. Rank hold IBIO as of Q2 2024.

  • FNY Investment Advisers reported no remaining iBio position as of Q2 2024 after selling out during the quarter.
  • FNY Investment Advisers sold 9,000 iBio shares in Q2 2024, an estimated $36.
  • FNY Investment Advisers first reported a position in iBio in Q1 2024 and held it in 1 quarter.
  • FNY Investment Advisers's iBio position peaked at $36 in Q1 2024.
  • 28 funds tracked by Wall St. Rank held iBio as of Q2 2024.

Based on FNY Investment Advisers's 13F filing for Q2 2024, filed 5 Aug 2024.